S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
$130 trillion revolution in this cup? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
$130 trillion revolution in this cup? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
$130 trillion revolution in this cup? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
$130 trillion revolution in this cup? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
NASDAQ:IMGN

ImmunoGen - IMGN Stock Forecast, Price & News

$4.85
+0.07 (+1.46%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.67
$4.95
50-Day Range
$4.48
$6.47
52-Week Range
$3.10
$7.77
Volume
2.81 million shs
Average Volume
3.38 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.80

ImmunoGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
102.1% Upside
$9.80 Price Target
Short Interest
Bearish
5.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.03mentions of ImmunoGen in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.89) to ($0.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

532nd out of 1,093 stocks

Pharmaceutical Preparations Industry

247th out of 548 stocks

IMGN stock logo

About ImmunoGen (NASDAQ:IMGN) Stock

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

Form 8-K ImmunoGen, Inc. For: Aug 31 - StreetInsider.com
ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript
See More Headlines
Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Company Calendar

Last Earnings
7/29/2022
Today
10/03/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
106
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$9.80
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+102.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-139,300,000.00
Net Margins
-179.64%
Pretax Margin
-179.64%

Debt

Sales & Book Value

Annual Sales
$69.86 million
Book Value
$1.61 per share

Miscellaneous

Free Float
213,341,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
0.97

Social Links


Key Executives

  • Mr. Mark Joseph EnyedyMr. Mark Joseph Enyedy (Age 58)
    Pres, CEO & Director
    Comp: $1.24M
  • Ms. Susan Altschuller Ph.D. (Age 39)
    Sr. VP & CFO
    Comp: $537.53k
  • Dr. Anna Berkenblit M.D. (Age 52)
    MM.Sc, Sr. VP & Chief Medical Officer
    Comp: $647.28k
  • Ms. Stacy A. Coen (Age 51)
    Sr. VP & Chief Bus. Officer
    Comp: $547.66k
  • Ms. Kristen Harrington-Smith (Age 49)
    Sr. VP & Chief Commercial Officer
    Comp: $562.52k
  • Ms. Renee Lentini (Age 44)
    VP of Fin. & Principal Accounting Officer
  • Ms. Courtney O'Konek
    Sr. Director of Corp. Communications & Investor Relations
  • Mr. Joseph J. Kenny
    VP, Acting Gen. Counsel, Intellectual Property & Sec.
  • Ms. Audrey Bergan
    Sr. VP & Chief HR Officer
  • Dr. Theresa G. Wingrove (Age 64)
    Sr. VP of Regulatory Affairs & Quality













IMGN Stock - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price forecast for 2022?

5 Wall Street research analysts have issued 1 year target prices for ImmunoGen's stock. Their IMGN share price forecasts range from $5.00 to $18.00. On average, they expect the company's share price to reach $9.80 in the next year. This suggests a possible upside of 102.1% from the stock's current price.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2022?

ImmunoGen's stock was trading at $7.42 at the beginning of the year. Since then, IMGN stock has decreased by 34.6% and is now trading at $4.85.
View the best growth stocks for 2022 here
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, July, 29th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biotechnology company earned $14.20 million during the quarter, compared to analysts' expectations of $16.18 million. ImmunoGen had a negative net margin of 179.64% and a negative trailing twelve-month return on equity of 67.02%. The business's revenue for the quarter was down 16.0% on a year-over-year basis. During the same period last year, the business earned ($0.15) earnings per share.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2022 earnings guidance on Friday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $75.00 million-$85.00 million, compared to the consensus revenue estimate of $84.73 million.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $4.85.

How much money does ImmunoGen make?

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $1.07 billion and generates $69.86 million in revenue each year. The biotechnology company earns $-139,300,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does ImmunoGen have?

The company employs 106 workers across the globe.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.

This page (NASDAQ:IMGN) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.